Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Disclosure under Chapter 9, Section 10 of the Securities Markets Act (Teemu Suna)

Nightingale Health Plc Company release 18 June 2024 at 5:05 p.m. (EEST)   Nightingale Health Plc (“Nightingale Health”) has received a notification on 18 June 2024 according to Chapter 9, Section 5 of the Finnish Securities Markets Act, stating that Teemu Suna’s votes exceed 10 % of all votes in Nightingale Health. Teemu Suna’s votes exceeded the notification threshold before April 19, 2024. The notification of exceeding the voting right threshold is retroactive because an amendment to the Securities Markets Act entered into force on 19 April 2024, according to which the

Circio Holding ASA - Approval and publication of prospectus for the rights issue

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.Oslo, 18 June 2024: Reference is made to the stock exchange announcements made by Circio Holding ASA (the "Company") on 29 May 2024, whereby the Company published the terms of the contemplated rights issue (the "Rights Issue") and related

Circio Holding ASA - Updated key information relating to the rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, HONG KONG, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.Oslo, 18 June 2024: Reference is made to the stock exchange announcement published by Circio Holding ASA (the "Company") on 29 May 2024 with key information relating to the rights issue in the Company (the "Rights Issue"). Please see

Circio Holding ASA - Updated information to the notice of annual general meeting 2024

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.Oslo, 18 June 2024: Reference is made to the notice of the annual general meeting of Circio Holding ASA published on 29 May 2024 and the annual general meeting to be held on Wednesday 19 June 2024 at 10:00 hours (CEST) as a physical meeting at the

SSAB’s updated climate goals approved by the Science Based Targets initiative

SSAB’s near- and long-term carbon emissions reduction targets have been approved by the Science Based Targets initiative (SBTi). Approval means that the targets are scientifically based and in line with the SBTi’s raised requirements for companies to deliver on the goal of limiting global warming to 1.5°C. SSAB’s now validated long-term target is to reach net-zero greenhouse gas emissions for Scope 1, Scope 2 and Scope 3 by 2045*. The updated near-term target is a reduction of 48 percent in greenhouse gas emissions in Scope 1, Scope 2 and parts of Scope 3 by 2033 compared with

Perineal cut reduces the risk of serious birth injury

In first-time mothers requiring vacuum-assisted delivery, a lateral episiotomy (angled cut) in the tissue between the vaginal and anal opening more than halves the risk of obstetric anal sphincter injury, a severe form of perineal trauma between the vulva and anus. This according to a randomised clinical study led by researchers at Karolinska Institutet and Stockholm’s Danderyd Hospital, the results of which are published in The BMJ.Obstetric Anal Sphincter Injury (OASI), which involves the anal sphincter muscles, can lead to anal incontinence with difficulties retaining gas and faeces. It

Raisio plc: Managers´ transactions

Raisio plc Managers´ transactions 18 June 2024   MANAGERS’ TRANSACTIONS   Person subject to the notification requirement Name: Arto Tiitinen Position: Member of the Board/Deputy member Issuer: Raisio Oyj LEI: 74370083282NHIP4QD02   Notification type: INITIAL NOTIFICATION Reference number: 66610/5/4 ____________________________________________   Transaction date: 2024-06-18 Outside a trading venue Instrument type: SHARE ISIN: FI0009002943 Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE   Transaction details (1): Volume:

Raisio plc: Managers´ transactions

Raisio plc Managers´ transactions 18 June 2024   MANAGERS’ TRANSACTIONS   Person subject to the notification requirement Name: Tero Hemmilä Position: Member of the Board/Deputy member Issuer: Raisio Oyj LEI: 74370083282NHIP4QD02   Notification type: INITIAL NOTIFICATION Reference number: 66616/4/4 ____________________________________________   Transaction date: 2024-06-18 Outside a trading venue Instrument type: SHARE ISIN: FI0009002943 Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE   Transaction details (1): Volume:

Raisio plc: Managers´ transactions 18 June 2024

Raisio plc Managers´ transactions 18 June 2024   MANAGERS’ TRANSACTIONS   Person subject to the notification requirement Name: Leena Niemistö Position: Member of the Board/Deputy member Issuer: Raisio Oyj LEI: 74370083282NHIP4QD02   Notification type: INITIAL NOTIFICATION Reference number: 66628/4/4 ____________________________________________   Transaction date: 2024-06-18 Outside a trading venue Instrument type: SHARE ISIN: FI0009002943 Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE   Transaction details (1): Volume:

Raisio plc: Managers´ transactions

Raisio plc Managers´ transactions 18 June 2024   MANAGERS’ TRANSACTIONS   Person subject to the notification requirement Name: Lauri Sipponen Position: Member of the Board/Deputy member Issuer: Raisio Oyj LEI: 74370083282NHIP4QD02   Notification type: INITIAL NOTIFICATION Reference number: 66637/4/4 ____________________________________________   Transaction date: 2024-06-18 Outside a trading venue Instrument type: SHARE ISIN: FI0009002943 Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE   Transaction details (1): Volume:

Raisio plc: Managers´ transactions

Raisio plc Managers´ transactions 18 June 2024   MANAGERS’ TRANSACTIONS   Person subject to the notification requirement Name: Ann-Christine Sundell Position: Member of the Board/Deputy member Issuer: Raisio Oyj LEI: 74370083282NHIP4QD02   Notification type: INITIAL NOTIFICATION Reference number: 66639/4/4 ____________________________________________   Transaction date: 2024-06-18 Outside a trading venue Instrument type: SHARE ISIN: FI0009002943 Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE   Transaction details (1):

Raisio plc: Managers´ transactions

Raisio plc Managers´ transactions 18 June 2024   MANAGERS’ TRANSACTIONS   Person subject to the notification requirement Name: Pekka Tennilä Position: Member of the Board/Deputy member Issuer: Raisio Oyj LEI: 74370083282NHIP4QD02   Notification type: INITIAL NOTIFICATION Reference number: 66645/4/4 ____________________________________________   Transaction date: 2024-06-18 Outside a trading venue Instrument type: SHARE ISIN: FI0009002943 Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE   Transaction details (1): Volume:

Experts from Dicot Pharma's clinical study behind submitted abstract

Uppsala, Sweden, June 18, 2024. The statistical analysis of Dicot Pharma's phase 1 data is now completed, reinforcing and deepening the results the company communicated in April after the end of the study. The results of the analysis will be published in an abstract submitted to North America's largest conference in the field and featuring some of the most prominent names within sexual medicine as co-authors.Dicot Pharma's statistical analysis of the Phase 1 study is completed. The analysis reinforces and deepens the results that were communicated instantly after the end of the study in

Terrafame has started uranium recovery

Terrafame has on 18 June 2024 started recovering natural uranium on its industrial site in Sotkamo, Finland. Before the recovery was commissioned, the Finnish Radiation and Nuclear Safety Authority (STUK) conducted a commissioning inspection at the uranium recovery plant and found that the plant can be commissioned safely.  The company’s production process enables the low concentration of natural uranium found in the ore to be used as a by-product. The uranium recovered by Terrafame will be transported abroad for further processing, after which it will be used in nuclear energy

Disclosure under Chapter 9, Section 10 of the Securities Markets Act (Antti Kangas)

Nightingale Health Plc Company release 18 June 2024 at 3:20 p.m. (EEST)   Nightingale Health Plc (“Nightingale Health”) has received a notification on 18 June 2024 according to Chapter 9, Section 5 of the Finnish Securities Markets Act, stating that Antti Kangas’s ownership of shares exceeds 5 % of all shares and votes exceed 20 % of all votes in Nightingale Health. Antti Kangas’s ownership and votes exceeded the notification threshold before April 19, 2024. The notification of exceeding the ownership and voting right threshold is retroactive because an amendment to the

Vår Energi ASA: Notification of trade by primary insider

Sandnes, Norway, 18 June 2024: Deputy employee representative to the Board, Trond Arvid Larsen in Vår Energi (OSE: VAR) has bought 2000 shares in the company at a price of NOK 34.3 per share. Following the purchase, Larsen holds a total of 10 550 shares in Vår Energi. This information is subject to the disclosure requirements pursuant to MAR article 19 and Section 5-12 the Norwegian Securities Trading Act. Contact Investor relations Ida Marie Fjellheim, Head of Investor Relations +47 90509291 ida.fjellheim@varenergi.no About Vår Energi Vår Energi is a leading

STENOCARE A/S: Notice for deadline of trading TO2 Warrants

STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENO Stenocare TO2 Warrant trading will end close of business June 19. To benefit from the discounted share price of DKK 3.16 each, subscribers need to own TO2 Warrants (ticker: STENO TO2).Stenocare is currently offering a time-limited share issue for owners of TO2 Warrants. These warrants can be purchased and/or sold until the deadline of June 19, 2024, at 17:00 Central European Summer Time. The TO2 Warrants can be used to subscribe to (purchase) the new Stenocare shares at a discounted price of DKK 3.16 each during

SOFTSWISS Game Aggregator Unveils Game Release Calendar

The SOFTSWISS Game Aggregator, a leading content hub for iGaming projects , launched a Game Release Calendar designed to enhance operators' convenience and operational efficiency.The Game Release Calendar provides operators with a weekly preview of upcoming game releases. It offers advance information about new providers joining the platform and anticipated new games from existing ones. This helps operators decide which games to acquire and plan their activities more effectively.

DanCann Pharma A/S: Solid growth in the Rx portfolio

COPENHAGEN, Denmark, 18 June 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby provides an update on its current portfolio and expectations for the year ahead.Key highlights from the portfolio[1] and pipeline[2]: · Growth in 2023: Achieved a sales growth of +40% year-over-year (YoY) in pharmacy sales. · Sales volume: This growth equated to +14,000 packages of medicine. · 2024 projections: The Company aims to further increase the current Rx portfolio sales volume to 20,000 packages in 2024, representing a

ExpreS2ion hosts informative webinar on 2024 Rights Issue and Highlights Key Updates on HER2+ Breast Cancer Vaccine

Hørsholm, Denmark, 18 June 2024 – ExpreS2ion Biotech Holding AB’s ("ExpreS2ion" or the "Company") (NASDAQ First North: EXPRS2) announces that its recent webinar covering the 2024 rights issue, hosted by CEO Bent Frandsen and CFO Keith Alexander, is now available for on-demand viewing. The webinar  provided insights into the background and rationale for the rights issue, detailed the intended use of proceeds, outlined the structure of the offering, and explained how to participate. Additionally, CEO Bent Frandsen has recently delivered significant presentations at

YIT selected as partner for the renovation of the Aleksanteri School in Tampere

YIT Corporation Press Release 18 June 2024 at 00:00 p.m.YIT has been selected as a project management contractor for the renovation project of the Aleksanteri School in Tampere, in addition to which YIT will act as main constructor for the project. The City of Tampere is the commissioner of the project. The project is implemented as a goal- and ceiling-priced cooperative project management contract, in which the project management contractor acts as the main constructor of the project. The cost estimate determined by the client for the project management contract is approximately EUR 20

theHunter: Call of the Wild’s “Sundarpatan Nepal Hunting Reserve” DLC Out Now on PlayStation, Xbox & PC

Expansive Worlds’ open-world fishing game Call of the Wild: The Angler also receives a new DLC & content update today STOCKHOLM – June 18, 2024 – Expansive Worlds, a creative division within Avalanche Studios Group, is excited today to release theHunter: Call of the Wild’s newest DLC, the “Sundarpatan Nepal Hunting Reserve,” on PlayStation, Xbox, and PC via Steam, the Epic Games Store and Microsoft Store. Available for $11.99/€11.79, with an additional 20% discount offered across all storefronts through June 24, this new location adds three sprawling regions to the acclaimed

SOFTSWISS Turns On Red Light at iGB L!VE 2024

SOFTSWISS, a global tech provider with over 15 years of experience in iGaming, is set to embark on one of the most anticipated industry events of the year – iGB L!VE.On 17–18 July, iGB L!VE will bring together game providers, operators, affiliates, and tech vendors for a dynamic live iGaming event. Encouraging robust, trust-based partnerships, iGB L!VE offers an opportunity to elevate business development and secure a competitive edge in the industry. The event welcomes around 10,000 gaming and affiliate stakeholders and over 300 exhibitors and sponsors. It unites the iGaming community

Calliditas provides setanaxib patent update

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the United States Patent and Trademark Office (USPTO) has issued a patent for application no. 16/760,910 entitled “Use of NOX Inhibitors for Treatment of Cancer.”The patent covers a method of treating a solid tumor presenting resistance to PD-1 inhibitor immunotherapy by administering setanaxib in combination with a PD-1 inhibitor. The patent will have an expiration date in 2039. Calliditas has corresponding applications and patents in several additional territories around the world,

There are no items matching the current filter
There are no more items matching the current filter
Back to top